Does the media refer more to XNCR or DNTH?

In the previous week, Dianthus Therapeutics had 1 more articles in the media than Xencor. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 9 mentions for Xencor. Dianthus Therapeutics' average media sentiment score of 1.39 beat Xencor's score of 0.44 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, XNCR or ERAS?

Xencor has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $97.36M 14.77 -$91.92M -$2.29 N/A Erasca N/A N/A -$124.55M -$0.93 N/A

Is XNCR or ERAS more profitable?

Erasca has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -177.10% -28.77% -20.52% Erasca N/A -35.31% -29.49%

Does the media refer more to XNCR or ERAS?

In the previous week, Erasca had 28 more articles in the media than Xencor. MarketBeat recorded 37 mentions for Erasca and 9 mentions for Xencor. Xencor's average media sentiment score of 0.44 beat Erasca's score of 0.25 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 8 Very Positive mention(s) 1 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, GRFS or XNCR?

Grifols has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.63 $454.82M $0.19 41.37 Xencor $97.36M 14.77 -$91.92M -$2.29 N/A

Is GRFS or XNCR more profitable?

Grifols has a net margin of 5.54% compared to Xencor's net margin of -177.10%. Grifols' return on equity of 6.21% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Xencor -177.10% -28.77% -20.52%

Does the media refer more to GRFS or XNCR?

In the previous week, Grifols and Grifols both had 9 articles in the media. Grifols' average media sentiment score of 0.93 beat Xencor's score of 0.44 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, TWST or XNCR?

Twist Bioscience has higher revenue and earnings than Xencor. Twist Bioscience is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $409.48M 15.37 -$77.67M -$1.33 N/A Xencor $97.36M 14.77 -$91.92M -$2.29 N/A

Is TWST or XNCR more profitable?

Twist Bioscience has a net margin of -19.85% compared to Xencor's net margin of -177.10%. Twist Bioscience's return on equity of -26.73% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Twist Bioscience -19.85% -26.73% -19.15% Xencor -177.10% -28.77% -20.52%

Does the media favor TWST or XNCR?

In the previous week, Twist Bioscience had 5 more articles in the media than Xencor. MarketBeat recorded 14 mentions for Twist Bioscience and 9 mentions for Xencor. Twist Bioscience's average media sentiment score of 1.24 beat Xencor's score of 0.44 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to XNCR or ORKA?

In the previous week, Xencor had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 9 mentions for Xencor and 7 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.25 beat Xencor's score of 0.44 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xencor (XNCR) Competitors

$19.40 -0.81 (-4.01%)

Closing price 04:00 PM Eastern

Extended Trading

$19.39 -0.01 (-0.05%)

As of 04:45 PM Eastern

Compare

XNCR vs. DNTH, ERAS, GRFS, TWST, and ORKA

Should you buy Xencor stock or one of its competitors? MarketBeat compares Xencor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xencor include Dianthus Therapeutics (DNTH), Erasca (ERAS), Grifols (GRFS), Twist Bioscience (TWST), and Oruka Therapeutics (ORKA).

How does Xencor compare to Dianthus Therapeutics?

Xencor (NASDAQ:XNCR) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Xencor has a net margin of -177.10% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

In the previous week, Dianthus Therapeutics had 1 more articles in the media than Xencor. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 9 mentions for Xencor. Dianthus Therapeutics' average media sentiment score of 1.39 beat Xencor's score of 0.44 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Xencor presently has a consensus price target of $24.25, indicating a potential upside of 25.00%. Dianthus Therapeutics has a consensus price target of $117.82, indicating a potential upside of 11.13%. Given Xencor's higher probable upside, equities research analysts plainly believe Xencor is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Xencor has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$97.36M	14.77	-$91.92M	-$2.29	N/A
Dianthus Therapeutics	$1.34M	4,338.09	-$162.34M	-$4.13	N/A

Summary

Dianthus Therapeutics beats Xencor on 9 of the 17 factors compared between the two stocks.

How does Xencor compare to Erasca?

Xencor (NASDAQ:XNCR) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Erasca had 28 more articles in the media than Xencor. MarketBeat recorded 37 mentions for Erasca and 9 mentions for Xencor. Xencor's average media sentiment score of 0.44 beat Erasca's score of 0.25 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	8 Very Positive mention(s)	1 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of Erasca shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Xencor has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$97.36M	14.77	-$91.92M	-$2.29	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Xencor has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Erasca has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Erasca has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Erasca	N/A	-35.31%	-29.49%

Xencor presently has a consensus target price of $24.25, indicating a potential upside of 25.00%. Erasca has a consensus target price of $21.64, indicating a potential upside of 21.28%. Given Xencor's higher probable upside, analysts clearly believe Xencor is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Xencor beats Erasca on 8 of the 15 factors compared between the two stocks.

How does Xencor compare to Grifols?

Grifols (NASDAQ:GRFS) and Xencor (NASDAQ:XNCR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Grifols has a net margin of 5.54% compared to Xencor's net margin of -177.10%. Grifols' return on equity of 6.21% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Xencor	-177.10%	-28.77%	-20.52%

In the previous week, Grifols and Grifols both had 9 articles in the media. Grifols' average media sentiment score of 0.93 beat Xencor's score of 0.44 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grifols has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.63	$454.82M	$0.19	41.37
Xencor	$97.36M	14.77	-$91.92M	-$2.29	N/A

Grifols currently has a consensus price target of $10.00, indicating a potential upside of 27.23%. Xencor has a consensus price target of $24.25, indicating a potential upside of 25.00%. Given Grifols' higher possible upside, equities analysts plainly believe Grifols is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Grifols has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Xencor has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Summary

Grifols beats Xencor on 9 of the 13 factors compared between the two stocks.

How does Xencor compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Xencor (NASDAQ:XNCR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Twist Bioscience presently has a consensus target price of $90.30, suggesting a potential downside of 10.65%. Xencor has a consensus target price of $24.25, suggesting a potential upside of 25.00%. Given Xencor's higher probable upside, analysts plainly believe Xencor is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Twist Bioscience has a net margin of -19.85% compared to Xencor's net margin of -177.10%. Twist Bioscience's return on equity of -26.73% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Xencor	-177.10%	-28.77%	-20.52%

In the previous week, Twist Bioscience had 5 more articles in the media than Xencor. MarketBeat recorded 14 mentions for Twist Bioscience and 9 mentions for Xencor. Twist Bioscience's average media sentiment score of 1.24 beat Xencor's score of 0.44 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Xencor	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Twist Bioscience has higher revenue and earnings than Xencor. Twist Bioscience is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$409.48M	15.37	-$77.67M	-$1.33	N/A
Xencor	$97.36M	14.77	-$91.92M	-$2.29	N/A

Twist Bioscience has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market. Comparatively, Xencor has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Summary

Twist Bioscience beats Xencor on 12 of the 14 factors compared between the two stocks.

How does Xencor compare to Oruka Therapeutics?

Xencor (NASDAQ:XNCR) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

56.4% of Oruka Therapeutics shares are held by institutional investors. 5.1% of Xencor shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Xencor presently has a consensus price target of $24.25, suggesting a potential upside of 25.00%. Oruka Therapeutics has a consensus price target of $134.30, suggesting a potential upside of 41.68%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Xencor had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 9 mentions for Xencor and 7 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.25 beat Xencor's score of 0.44 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Oruka Therapeutics' return on equity of -26.16% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Xencor has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, suggesting that its stock price is 135% less volatile than the broader market.

Xencor has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$97.36M	14.77	-$91.92M	-$2.29	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Summary

Oruka Therapeutics beats Xencor on 9 of the 15 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XNCR vs. The Competition

Export

Metric	Xencor	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.44B	$3.51B	$6.81B	$12.68B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-8.47	7.32	281.02	25.13
Price / Sales	14.77	1,219.72	575.02	81.09
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	2.18	16.89	11.02	6.21
Net Income	-$91.92M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-2.32%	-0.63%	0.57%	0.89%
1 Month Performance	29.33%	-7.40%	-4.14%	-3.60%
1 Year Performance	143.11%	49.17%	63.23%	20.46%

Xencor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XNCR Xencor	2.8425 of 5 stars	$19.40 -4.0%	$24.25 +25.0%	+153.3%	$1.44B	$97.36M	N/A	280	Upcoming Earnings
DNTH Dianthus Therapeutics	2.3246 of 5 stars	$103.27 -1.2%	$117.82 +14.1%	+419.3%	$5.65B	$2.04M	N/A	80	Positive News Upcoming Earnings
ERAS Erasca	2.5435 of 5 stars	$18.18 -3.7%	$21.64 +19.0%	+1,205.8%	$5.65B	N/A	N/A	120	Gap Down
GRFS Grifols	4.4713 of 5 stars	$7.97 +2.8%	$10.00 +25.5%	-27.0%	$5.42B	$8.51B	41.93	25,247	Analyst Downgrade
TWST Twist Bioscience	1.5441 of 5 stars	$86.76 +0.3%	$90.30 +4.1%	+171.8%	$5.40B	$409.48M	N/A	990	Trending News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XNCR) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xencor (XNCR) Competitors

XNCR vs. DNTH, ERAS, GRFS, TWST, and ORKA

How does Xencor compare to Dianthus Therapeutics?

Summary

How does Xencor compare to Erasca?

Summary

How does Xencor compare to Grifols?

Summary

How does Xencor compare to Twist Bioscience?

Summary

How does Xencor compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xencor (XNCR) Competitors

XNCR vs. DNTH, ERAS, GRFS, TWST, and ORKA

How does Xencor compare to Dianthus Therapeutics?

Is XNCR or DNTH more profitable?

Does the media refer more to XNCR or DNTH?

Which has more volatility & risk, XNCR or DNTH?

Do analysts prefer XNCR or DNTH?

Do institutionals & insiders believe in XNCR or DNTH?

Which has preferable earnings & valuation, XNCR or DNTH?

Summary

How does Xencor compare to Erasca?

Does the media refer more to XNCR or ERAS?

Do insiders & institutionals believe in XNCR or ERAS?

Which has better valuation and earnings, XNCR or ERAS?

Which has more volatility & risk, XNCR or ERAS?

Is XNCR or ERAS more profitable?

Do analysts rate XNCR or ERAS?

Summary

How does Xencor compare to Grifols?

Is GRFS or XNCR more profitable?

Does the media refer more to GRFS or XNCR?

Which has higher valuation & earnings, GRFS or XNCR?

Do analysts recommend GRFS or XNCR?

Which has more risk and volatility, GRFS or XNCR?

Summary

How does Xencor compare to Twist Bioscience?

Do analysts prefer TWST or XNCR?

Is TWST or XNCR more profitable?

Does the media favor TWST or XNCR?

Which has stronger earnings & valuation, TWST or XNCR?

Which has more volatility & risk, TWST or XNCR?

Summary

How does Xencor compare to Oruka Therapeutics?

Do insiders & institutionals have more ownership in XNCR or ORKA?

Do analysts recommend XNCR or ORKA?

Does the media refer more to XNCR or ORKA?

Is XNCR or ORKA more profitable?

Which has more risk & volatility, XNCR or ORKA?

Which has higher earnings & valuation, XNCR or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools